UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

Novo CEO: Correcting course after troubling setbacks

Tracy Staton Novo Nordisk's quarterly sales hit 21.38 billion kroner, or about $ 3.8 billion. Profits amounted to 6.7 billion kroner. And now, the company expects 2013 ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS